The pancreatic cancer microenvironment: An immunologic battleground

OncoImmunology

Volumn 3, Issue 8, 2014, Pages

  Pillarisetty, Venu G ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

IDO; Immune checkpoints; Myeloid cells; PD 1; Regulatory T cells

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84921689393     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.950171     Document Type: Article

References (10)

1. Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 2013; 25:200-5; PMID:23422836; http://dx.doi.org/10.1016/j. coi.2013.01.006
2. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 Agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-6; PMID:21436454; http://dx.doi.org/ 10.1126/science.1198443
3. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/ jem.20101876
4. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013; 108:914-23; PMID:23385730; http://dx.doi.org/ 10.1038/bjc.2013.32
5. Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 2014; 9:e96565; PMID:24794217; http:// dx.doi.org/10.1371/journal.pone.0096565
6. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34; PMID:17000676
7. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.org/10.1172/JCI73639
8. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/ 10.1126/scitranslmed.3003689
9. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma tumor microenvironment is driven by CD8 +T Cells. Sci Transl Med 2013; 5:200ra116-6; PMID:23986400; http://dx. doi.org/10.1126/scitranslmed.3006504
10. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694